Literature DB >> 28259239

Long-Term Comparative Outcomes of Patients With Peripheral Artery Disease With and Without Concomitant Coronary Artery Disease.

Debbie C Chen1, Gagan D Singh2, Ehrin J Armstrong3, Stephen W Waldo3, John R Laird2, Ezra A Amsterdam4.   

Abstract

There are limited contemporary data on guideline-directed medical therapy (GDMT) utilization and long-term clinical outcomes in patients with peripheral artery disease (PAD) with and without concomitant coronary artery disease (CAD). From 2006 to 2013, 879 patients with claudication or critical limb ischemia (CLI) underwent diagnostic angiography or therapeutic endovascular intervention at our multidisciplinary vascular center. GDMT use was assessed at the time of angiography, and major adverse cardiovascular and cerebrovascular events (MACCE) and all-cause mortality were determined during 5 years of follow-up. Cox proportional hazard modeling was used to adjust for baseline differences between patients with and without concomitant CAD. Despite a higher adherence to GDMT (all p ≤0.002) for the use of aspirin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, and statins, patients with PAD and concomitant CAD had higher unadjusted 5-year rates of MACCE (hazard ratio [HR] 1.7, 95% CI 1.3 to 2.1, p = 0.0001) and all-cause mortality (HR 1.86, 95% CI 1.4 to 2.4, p = 0.0001). After adjustment for baseline co-morbidities, the presence of CAD remained an independent risk factor for mortality (adjusted HR 1.35, 95% CI 1.02 to 1.80, p = 0.04) but not for MACCE (adjusted HR 1.24, 95% CI 0.96 to 1.60, p = 0.10) in patients with PAD. A sensitivity analysis limited to patients with CLI demonstrated that concomitant CAD was associated with significantly higher adjusted rates of both MACCE (adjusted HR 1.52, 95% CI 1.14 to 2.03, p = 0.01) and mortality (adjusted HR 1.64, 95% CI 1.12 to 2.20, p = 0.006). In conclusion, despite higher rates of GDMT use, PAD patients with concomitant CAD had significantly increased risk of all-cause mortality during a 5-year postprocedural follow-up. The subgroup of CLI patients with concomitant CAD was at particularly high risk for both MACCE and all-cause mortality.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28259239     DOI: 10.1016/j.amjcard.2016.12.023

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Sex-Related Differences in the Outcomes of Endovascular Interventions for Chronic Limb-Threatening Ischemia: Results from the LIBERTY 360 Study.

Authors:  Stefanos Giannopoulos; Nicolas W Shammas; Ian Cawich; Cezar S Staniloae; George L Adams; Ehrin J Armstrong
Journal:  Vasc Health Risk Manag       Date:  2020-07-08

2.  Myocardial injury after endovascular revascularization in critical limb ischemia predicts 1-year mortality: a prospective observational cohort study.

Authors:  Wojciech Szczeklik; Marek Krzanowski; Paweł Maga; Łukasz Partyka; Jolanta Kościelniak; Paweł Kaczmarczyk; Mikołaj Maga; Patrycja Pieczka; Anna Suska; Agnieszka Wachsmann; Jacek Górka; Bruce Biccard; P J Devereaux
Journal:  Clin Res Cardiol       Date:  2017-11-24       Impact factor: 5.460

3.  Three-Year Outcomes of Orbital Atherectomy for the Endovascular Treatment of Infrainguinal Claudication or Chronic Limb-Threatening Ischemia.

Authors:  Stefanos Giannopoulos; Eric A Secemsky; Jihad A Mustapha; George Adams; Robert E Beasley; George Pliagas; Ehrin J Armstrong
Journal:  J Endovasc Ther       Date:  2020-07-03       Impact factor: 3.487

4.  Novel Insight Into Long-Term Risk of Major Adverse Cardiovascular and Cerebrovascular Events Following Lower Extremity Arteriosclerosis Obliterans.

Authors:  Ji Sun; Qiang Deng; Jun Wang; Shoupeng Duan; Huaqiang Chen; Huixin Zhou; Zhen Zhou; Fu Yu; Fuding Guo; Chengzhe Liu; Saiting Xu; Lingpeng Song; Yijun Wang; Hui Feng; Lilei Yu
Journal:  Front Cardiovasc Med       Date:  2022-04-04

5.  Social, demographic and clinical characteristics of patients suffering from peripheral vascular disease treated surgically compared to patients treated with endovascular angioplasty.

Authors:  Renata Piotrkowska; Marek Dobosz; Janina Książek; Grzegorz Halena
Journal:  Arch Med Sci Atheroscler Dis       Date:  2017-06-23

6.  Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices.

Authors:  Michael D Dake; Gary M Ansel; Marc Bosiers; Andrew Holden; Osamu Iida; Michael R Jaff; Aaron E Lottes; Erin E O'Leary; Alan T Saunders; Marc Schermerhorn; Hiroyoshi Yokoi; Thomas Zeller
Journal:  Cardiovasc Intervent Radiol       Date:  2019-09-09       Impact factor: 2.740

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.